Skip to main content
Signal8
Launch Terminal

Satellos Bioscience Inc. (MSLE)

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Satellos Bioscience Inc. Common Stock logo

Satellos Bioscience Inc. Common Stock

NASDAQ:MSLEHealthcare
-1.69%$6.70
Mkt Cap$142.15M
Float18.81M
O/S21.22M
Vol
$ Vol
RVOL
Inst Own36.2%
SI0.5%
Earnings
Dilution
Satellos Bioscience Inc. Common Stock logoNASDAQ:MSLE$6.70-1.69%
FormDescription
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
2
6-K
Foreign Private Issuer Report
2
6-K
Foreign Private Issuer Report
3
6-K
Foreign Private Issuer Report
3
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
3
SUPPL
SEC Filing
6-K
Foreign Private Issuer Report
7
F-X
SEC Filing
1
F-10
SEC Filing
9
6-K
Foreign Private Issuer Report
2
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
1
6-K
Foreign Private Issuer Report
6-K
Foreign Private Issuer Report
13G
Beneficial Ownership Report
6-K
Foreign Private Issuer Report
3
13G
Beneficial Ownership Report
6-K
Foreign Private Issuer Report
S-8
SEC Filing

1-25 of 53

    Satellos Bioscience Inc. (MSLE) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8